Precision BioSciences Director Adds 22% More Shares in Open-Market Deal

Rhea-AI Filing Summary

Precision BioSciences (NASDAQ: DTIL) filed a Form 4 disclosing that director Kevin Buehler purchased 5,076 shares of common stock on 25 Jun 2025 at a weighted-average price of $4.16 per share (trade range: $4.16–$4.18). After the transaction, Buehler directly owns 28,137 shares, an increase of roughly 22% in his personal stake. The transaction was coded “P” for an open-market purchase, and the filing reports no sales or derivative security activity. No Rule 10b5-1 trading plan was indicated.

Positive

• Director Kevin Buehler increased his direct ownership by 5,076 DTIL shares (+22%) through an open-market purchase at an average $4.16 price

Negative

• None.

Insights

Event Analyst

TL;DR: Small insider buy shows modest confidence; impact likely neutral.

The Form 4 reveals a roughly $21 k open-market purchase by director Kevin Buehler, lifting his direct holdings by about 22% to 28,137 shares. While the percentage increase exceeds the 5% materiality threshold, the dollar value is immaterial relative to Precision BioSciences’ capitalization, so immediate market impact should be limited. Absence of concurrent sales or option exercises offers a marginally positive sentiment signal but not a decisive catalyst.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Buehler Kevin

(Last) (First) (Middle)

C/O PRECISION BIOSCIENCES, INC.

302 E. PETTIGREW ST, SUITE A-100

(Street)

DURHAM NC 27701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2025		P		5,076	A	$4.16(1)	28,137	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.16 to $4.18. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Dario Scimeca, Attorney-in-fact for Kevin Buehler	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many DTIL shares did director Kevin Buehler buy on June 25, 2025?

He purchased 5,076 shares of Precision BioSciences common stock.

What was the average purchase price for the shares acquired by DTIL's director?

The weighted-average price was approximately $4.16 per share, with transactions between $4.16 and $4.18.

What is Kevin Buehler's total direct ownership in DTIL after the transaction?

Following the purchase, Buehler directly owns 28,137 shares of DTIL.

Did the filing disclose any sales or derivative transactions by the director?

No. The Form 4 lists only an open-market purchase of common stock and shows no derivative activity.

Was the purchase made under a Rule 10b5-1 trading plan?

The filing does not indicate the use of a Rule 10b5-1(c) plan; the relevant checkbox was left blank.